Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Madison Dividend Income Fund's investment thesis on Charles River Laboratories International, Inc. ($CRL) — Q1 2026 | Buyside Digest

$CRLNYSECharles River Laboratories International, Inc.

BULL

Madison Dividend Income Fund—CRL

Fund Letter

Q1 2026

Published April 18, 2026

$295.01USD

+2.3% vs last month

$169.80Pitched

+73.7% since pitch

Market CapN/A

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.

— John Brown, Drew Justman

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on Charles River Laboratories International, Inc.

No other institutional pitches found for this ticker yet.